Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies

Next Previous
Search
Trial Profile

A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Epizyme

    • Most Recent Events

    • 31 Jan 2025 Planned End Date changed from 28 Jun 2025 to 17 Jun 2025.
    • 31 Jan 2025 Planned primary completion date changed from 3 Jun 2025 to 20 May 2025.
    • 26 Apr 2024 Planned End Date changed from 30 Jun 2025 to 28 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top